Name of the Issue: 1 Type of Issue Initial Public Offer 2 Issue Size (Rs. Mn) 13,305.10 *Source: Prospectus dated December 12, 2016 3 Grade of issue along with name of the rating agency Name Grade NA NA 4 Subscription Level (Number of times) 3.50 * Figure is after technical rejections Source: Basis of allotment 5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges Particulars %age (i) On Allotment ** 4.74% (ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2016)** (iii) at the end of 1st FY (March 31, 2017)** 53.78% (iv) at the end of 2nd FY (March 31, 2018) ** 50.64% (v) at the end of 3rd FY (March 31, 2019) * * QIB Holding not disclosed as reporting for relevant period has not been completed. Source: ** Basis of Allotment 6 Financials of the issuer (Rs. Million) 1st FY (March 2nd FY (March 3rd FY (March Parameters 31,2017) 31,2018) 31,2019) * Income from operations 19,315 20,690 Not Available Net Profit for the period 1,913 1,676 Not Available Paid-up equity share capital 1,058 1,060 Not Available Reserves 1,225 13,766 Not Available * Financials not available as reporting for the relevant years has not been completed. Source: Company filings 53.46% N.A.
7 Trading Status The equity shares of are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges") The equity shares have not been suspended or delisted. Particulars (i) at the end of 1st FY (March 31, 2017) (ii) at the end of 2nd FY (March 31, 2018) * Status Frequentrly traded Frequentrly traded (iii) at the end of 3rd FY (March 31, 2019) * Not Available * Trading status not disclosed as the relevant fiscal years have not been completed. Source: Stock exchange data. 8 Change in Directors of Issuer from the disclosures in the offer document Particulars Name of Director Appointed / Resigned (i) at the end of 1st FY (March 31, 2017) Massimo Venuti Appointed Asanka Rodrigo Resigned (ii) at the end of 2nd FY (March 31, 2018) Rajesh Dugar Resigned Dr. Srihari Raju Kalidindi Dr. Venkata Lakshmana Rao Chunduru Resigned Appointed (iii) at the end of 3rd FY (March 31, 2019) * Not Available Not Available * Changes in Directors of Issuer not updated as the relevant financial years have not been completed 9 Status of implementation of project/ commencement of commercial production (i) as disclosed in the offer document (ii) Actual implementation (iii) Reasons for delay in implementation, if any
10 Status of utilization of issue proceeds (i) As disclosed in the offer document (Rs. Million) Particulars Total estimated fund requirement Fiscal 2017 Fiscal 2018 Prepayment of term loans 2,263 2,263 - General Corporate Purposes 604 604 - Note: As disclosed in the prospectus (ii) Actual utilization Particulars Total estimated fund requirement Fiscal 2017 Fiscal 2018 Prepayment of term loans 2,263 2,263 - General Corporate Purposes 604 596 - (iii) Reasons for deviation, if any 11 Comments of monitoring agency, if applicable (i) Comments on use of funds (ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document (iii) Any other reservations expressed by the monitoring agency about the end use of funds
12 Pricing Data Designated Stock Exchange NSE Issue Price (Rs.) 428.00 Listing Date 19-Dec-16 Price parameters At close of listing day December 19, 2016 Close of 30th calendar day from listing day Close of 90th calendar day from listing day As at the end of the 1st FY after the listing of the issue ( 31st March,2017) Closing price High Low Market Price 480.40 478.10 530.60 516.20 559.85 455.20 CNX NIFTY 8104.35 8,417.0 9,160.1 9,173.8 9,173.8 7,546.5 Price parameters As at the end of the 2nd FY after the listing of the issue ( 31st March,2018) (1) Closing price High Low Closing price High Low Market Price 502.9 628.4 502.2 Not Available Not Available Not Available CNX NIFTY 10,113.7 11,130.4 9,103.5 Not Available Not Available Not Available * Being index of BSE, the designated stock exchange (1) The pricing data is not disclosed as the relevant fiscal years have not been completed As at the end of the 3rd FY after the listing of the issue ( 31st March,2019) (1)
13 Basis for Issue Price Accounting ratio EPS (Basic) P/E As disclosed in offer document* At the end of 1st FY (March 31,2017)** At the end of 1st FY (March 31,2018)*** At the end of 1st FY (March 31,2019)*** 20.86 18.79 15.83 Not Available 37.81 34.42 37.2 Not Available 20.52 27.47 31.77 Not Available 26.03 22.93 23.24 Not Available RoNW 15.57% 14.30% 11.30% Not Available 30.37% 19.85% 17.77% Not Available NAV per share 135.06 125.8 139.83 Not Available 141.56 173.87 211.28 Not Available Notes * Sourced and caculated as per Prospectus dated December 12, 2016 and Company filings uploaded on the stock exchange websites ***Not available as the relevant fiscal years have not been completed 14 Any other material information ** Peer groups include Divis Laboratories Ltd. amd Aurobindo Pharma Limited Particulars Date Remarks Laurus Labs Ltd has informed BSE that consequent to listing of equity shares of the Company on the Stock Exchanges 29-Dec-16 Laurus Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 09,2017, inter alia, to consider and approve the Unaudited Financial Results of the Companyfor the Quarter and 9 months period ended December 31, 2016. Further, the Company s trading window for dealing in securities by the Directors and Designated Persons shall be closed from February 03, 2017 to February 11, 2017 (both days inclusive) Mr. Frank J Wright (DIN 01609467), the Director of the Company, has tendered his resignation from the Board of the Company with effect from March 31, 2017. A copy of the said resignation letter received by the Company is attached for your information and records Company's pharmaceutical formulation & marketing partner Natco Pharma Ltd ('Natco') has launched the generic version of Sofosbuvir 400 mg/ Velpatasvir 100 mg fixed dose combination in India based on an API supplied by the Company The API facility of the Unit 2 has completed successful USFDA inspection without any 483 and the formulations unit in the same facility received EIR (Establishment Inspection Report) on May 18, 2017 Laurus Labs receives the EIR from USFDA, and also successfully completes the German Regulatory Authority for Unit 2 and WHO inspections for Units 1 & 3. 2-Feb-17 27-Mar-17 8-May-17 19-May-17 15-Sep-17
Particulars Date Remarks Laurus Labs Limited has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its Unit 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in August 2017 14-Nov-17 1-Mar-18 USFDA audit successfully completed without observations - ZERO 483 for its Unit 2 (formulations unit). The inspection was carried out from 26th Feb 2018-1st March 2018. Laurus Labs Ltd has also received its maiden Approval from United States Food and Drug Administration (U.S FDA) for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate Tablets 300mg is therapeutically equivalent to VIREAD Tablets 300mg of Gilead Science Ltd. (GILEAD). Tenofovir Disoproxil Fumarate Tablets 300mg is used for treatment of HIV-1 infection in adults and paediatric patients 2 years of age and older Note: For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com
DISCLAIMER: The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the Circular ) for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance. The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as www.capitalmarkets.com and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise. The information disclosed on this website is updated as of June 12, 2018. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.